ClinicalTrials.gg
RecruitingNCT06270108RESTOREUpdated Mar 5, 2024

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

An Early Phase 1 interventional study of Riluzole in Treatment-resistant Schizophrenia, Treatment-responsive Schizophrenia and Healthy Controls, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by King's College London · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Nov 2022, registered Jan 2024).
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
288
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this basic science study is to to explore the responsivity of glutamate in the brain of treatment-resistant schizophrenia patients to the drug riluzole. The main aims of the study are:

To assess the role of glutamate in treatment-resistant schizophrenia using magnetic resonance spectroscopy.

To assess the relationship between glutamate levels and brain structural and functional measures (using: structural MRI; functional MRI (fMRI) and arterial spin labelling (ASL)) at baseline.

To assess the relationship between longitudinal change in glutamate levels and brain structural and functional measures.

To assess the relationship between longitudinal change in glutamate levels and changes in psychopathology.

The researchers will compare the changes with healthy controls and those without treatment-resistant schizophrenia.

02

Conditions studied

  • Treatment-resistant Schizophrenia
  • Treatment-responsive Schizophrenia
  • Healthy Controls

Keywords

  • schizophrenia
  • treatment-resistant schizophrenia
  • glutamate
  • riluzole
03

In context

Schizophrenia, Treatment-Resistant

54 studies on the registry are indexed under Schizophrenia, Treatment-Resistant; 23 are open to participants now.

This study's planned enrollment of 288 is above the median of 60 across 46 interventional studies indexed under Schizophrenia, Treatment-Resistant.

Browse Schizophrenia, Treatment-Resistant studies →

Lead sponsor

King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria for treatment-resistant schizophrenia patients:

  1. Aged 18 years old or older;
  2. Diagnosis of schizophrenia or other psychotic disorder (-5 (DSM-5);
  3. Treatment resistance according to the Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus criteria. This requires a PANSS score of more than 70 and the presence of at least one positive and one negative symptom rated as ≥ 4 on the Positive and Negative Syndrome Scale (PANSS) and at least moderate functional impairment on the Social and Occupational Function Assessment Scale (SOFAS) despite at least 2 adequate trials of different antipsychotics;
  4. On a stable dose of antipsychotic (no dose changes in the past 1 month);
  5. Able to give fully informed written consent and likely to comply with the requirements of the study, after reading the information and consent form, and after having the opportunity to discuss the study with the investigator or his delegate;
  6. Capacity to provide , as judged by an investigator and as assessed by the McArthur scale;
  7. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of the entire study.

Exclusion criteria for treatment-resistant schizophrenia patients:

  1. History of significant co-morbid central nervous system (CNS) disorder (including significant head trauma or significant loss of consciousness, Parkinson's Disease, Epilepsy, Alzheimer's Dementia, Huntington's Disease);
  2. Current use of medication with recognized effect on glutamatergic signaling (e.g. lamotrigine, lithium, carbamazepine, opiates, and psychostimulants) OR medication that is known to interact with riluzole (eg: ciprofloxacin, combined hormonal , enoxacin, fluvoxamine, charcoal boiled (grilled) foods, methoxasalen, rucaparib, osilodrostat, mexiletine, nicergoline, pipemidic acid, rifampicin, tiabendazole, vemurafenib);
  3. Any absolute to riluzole according to the British National Formulary (such as interstitial lung disease, current pregnancy or lactation, severe hepatic impairment liver function tests more than 3x , acute porphyria, pancreatitis);
  4. Pregnancy and/or breast-feeding;
  5. Substance dependence/abuse other than to cigarettes;
  6. Current high suicide risk or other significant safety risk as judged by the patient's psychiatrist or study physician;
  7. Current homicidal ideation or intent;
  8. Participation in a clinical study of unlicensed medicines within the previous 30 days;
  9. abnormal findings at the screening assessment as judged significant by the principal investigator (e.g.: history of liver disease or transaminases more than 2 times the upper limit of normal);
  10. Presence of other acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the study or raise safety concerns;
  11. Any risk factors for liver damage (eg. alcohol dependence or history of liver disease) or patients who are receiving potentially hepatotoxic medications;
  12. Likelihood that the subject will not comply with study requirements or other reason the investigator judges the subject is not suitable;
  13. Objection by subject's physician;
  14. Any contraindication to MRI scanning (e.g. metallic implants);
  15. Any comorbidity that could compromise scanning safety (e.g. severe asthma).

Inclusion criteria for treatment-responsive schizophrenia patients:

  1. Aged 18 years old or older;
  2. Diagnosis of schizophrenia or other psychotic disorder (Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5);
  3. On a stable dose of antipsychotic (no dose changes in the past 1 month);
  4. Able to give fully informed written consent and likely to comply with the requirements of the study, after reading the information and consent form, and after having the opportunity to discuss the study with the investigator or his delegate;
  5. Capacity to provide informed consent, as judged by an investigator and as assessed by the McArthur scale;
  6. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of the entire study.

Exclusion criteria for treatment-responsive schizophrenia patients:

  1. Treatment resistance according to the Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus criteria;
  2. History of significant co-morbid CNS disorder (including significant head trauma or significant loss of consciousness, Parkinson's Disease, Epilepsy, Alzheimer's Dementia, Huntington's Disease);
  3. Substance dependence/abuse other than to cigarettes;
  4. Current high suicide risk or other significant safety risk as judged by the patient's psychiatrist or study physician;
  5. Current homicidal ideation or intent;
  6. Participation in a clinical study of unlicensed medicines within the previous 30 days;
  7. Likelihood that the subject will not comply with study requirements or other reason the investigator judges the subject is not suitable;
  8. Objection by subject's physician;
  9. Any contraindication to MRI scanning (e.g. metallic implants);
  10. Any comorbidity that could compromise scanning safety (e.g. severe asthma);

Inclusion criteria

Inclusion criteria for healthy controls:

  1. Aged 18 years old or older;
  2. No diagnosis of schizophrenia, schizophreniform or any psychotic disorder;
  3. Sufficient understanding of the nature of the study and any hazards of participating in it;
  4. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of the entire study;
  5. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the study with the investigator or his delegate;
  6. Capacity to provide informed consent, as judged by an investigator.

Exclusion criteria

Exclusion criteria for healthy controls

  1. Co-morbid psychiatric or other CNS disorder;
  2. Family history of Schizophrenia or Psychotic disorders;
  3. History of head trauma or loss of consciousness;
  4. Substance dependence/abuse other than to cigarettes;
  5. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the study or make it unnecessarily hazardous and judge significant by the principal investigator;
  6. Likelihood that the volunteer will not comply with the requirements of the study or other reason the investigator judges the subject is not suitable;
  7. Objection by a General Practitioner (GP), or another doctor responsible for their treatment, to the healthy control entering study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    Treatment-resistant schizophrenia patients receiving riluzole

    Drug: Riluzole

  • No intervention
    Treatment-responsive schizophrenia patients
  • No intervention
    Healthy controls

Interventions

  • 50mg twice daily (100mg total daily) for 56 days.

06

What researchers measure

Primary outcomes

  1. Change in glutamate levels (using magnetic resonance spectroscopy) pre- and post-riluzole administration

    Change in glutamate levels will be assessed (using magnetic resonance spectroscopy) in treatment-resistant schizophrenia patients compared with controls and patients without treatment-resistant schizophrenia

    Time frame: Brain measurements will be conducted at baseline (day -7 to day -1 before riluzole administration), day 7 and day 56 (+- 14 days)

Secondary outcomes

  1. Correlation of glutamate (using magnetic resonance spectroscopy) with brain functional measures at baseline (using functional magnetic resonance imaging)

    Time frame: Brain measurements will be conducted at baseline (day -7 to day -1 before riluzole administration), day 7 and day 56 (+- 14 days)

  2. Longitudinal change in glutamate levels (using magnetic resonance spectroscopy) correlated with longitudinal change in brain functional measures (using functional magnetic resonance imaging)

    Time frame: Brain measurements will be conducted at baseline (day -7 to day -1 before riluzole administration), day 7 and day 56 (+- 14 days)

  3. Longitudinal change in glutamate levels (using magnetic resonance spectroscopy) correlated with changes in psychopathology

    Changes in psychopathology assessed using rating scales Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression scale (CGI), Calgary Depression Scale for Schizophrenia (CDSS), Montgomery and Asberg Depression Rating Scale (MADRS), Hopkins Verbal Learning Test (HVLT) and a computerised cognitive task

    Time frame: Brain measurements will be conducted at baseline (day -7 to day -1 before riluzole administration), day 7 and day 56 (+- 14 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2024
First posted
Feb 21, 2024
StartActual
Nov 14, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06270108
Collaborators
South London and Maudsley NHS Foundation Trust
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
Nov 14, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 5, 2024

Study contacts

James Scott
Contact
james.1.scott@kcl.ac.uk
+44 207 848 0002
Guy Gitlin-Leigh
Contact
guy.1.gitlin-leigh@kcl.ac.uk
Oliver D Howes
principal investigator · King's College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riluzole

Start the discussion